Wells Fargo cuts Alnylam target to USD 253 for Alnylam Pharmaceuticals stock

Published on 10/20/2026 at 19:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 29, 2026. Alnylam Pharmaceuticals stock costs EUR 205.15 on October 20, 2026, 2.36 percent below Tradegate.

Analyst target and reporting date

Wells Fargo cut its Alnylam target to USD 253.00 on October 14, 2026.
Alnylam Pharmaceuticals is scheduled to report third-quarter results on October 29, 2026.
Alnylam Pharmaceuticals stock costs EUR 205.15 at Lang & Schwarz on October 20, 2026 at 7:12 p.m. CEST, 2.36 percent below the Tradegate close of October 16, 2026.
The Nasdaq stock had a USD 30.9 billion market capitalization and a 39.02 price-to-earnings ratio on October 20, 2026.

Alnylam Pharmaceuticals, US02043Q1076, Illustration mit AI erstellt.

Wells Fargo cut its Alnylam Pharmaceuticals price target from USD 256.00 to USD 253.00 on October 14, 2026, while maintaining an Equal Weight rating, according to MarketBeat. Alnylam Pharmaceuticals stock was trading at EUR 205.15 at Lang & Schwarz on October 20, 2026 at 7:12 p.m. CEST, down 2.36 percent versus the Tradegate close of October 16, 2026 at EUR 210.10.

Target cut meets strong earnings growth

The target reduction came despite Alnylam's second-quarter revenue reaching USD 1.29 billion, up 66.90 percent from the same period a year earlier. MarketBeat reported that quarterly earnings per share reached USD 1.84, above the USD 1.63 consensus estimate, while revenue remained below the USD 1.32 billion estimate.

The contrast is material for investors. Wells Fargo kept its rating at Equal Weight while reducing the target by USD 3.00, a 1.17 percent cut from USD 256.00. The same report cited expectations around AMVUTTRA sales and the outlook for the company's next growth phase.

Stock remains below its yearly high

On the Nasdaq, Alnylam stock was last quoted at USD 230.93 on October 20, 2026 at 1:20 p.m. EDT. The 52-week range was USD 197.81 to USD 490.05, placing the quote 52.88 percent below the high. The company had a market capitalization of USD 30.9 billion and a price-to-earnings ratio of 39.02 on the same date.

Alnylam Pharmaceuticals is a biotechnology company focused on RNA interference medicines. Its primary listing is Nasdaq under the ticker ALNY, and the company is a Nasdaq-100 constituent in the Health Care sector.

October 29 results set the next date

Alnylam announced on October 15, 2026 that it will report third-quarter results for the period ending September 30, 2026 before the U.S. market opens on October 29, 2026. The company also scheduled an 8:30 a.m. ET conference call, according to its investor release.

Comparison with peers

Alnylam Pharmaceuticals: down 2.36 percent, price-to-earnings ratio 39.02, market capitalization USD 30.9 billion.

Ionis Pharmaceuticals (Nasdaq, USD): up 1.53 percent, price-to-earnings ratio minus 12.98, market capitalization USD 7.5 billion.

Sarepta Therapeutics (Nasdaq, USD): up 9.49 percent, price-to-earnings ratio minus 6.70, market capitalization USD 2.1 billion.

Target and price remain in tension

The latest Wells Fargo target is 9.55 percent above the USD 230.93 Nasdaq quote, using the same currency and the October 20, 2026 price. The euro quotation was lower than the dated Tradegate close, giving the stock report a weaker short-term tone while the upcoming results date keeps attention on execution.

The further course of trading is shown by the continuously updated real-time quote of Alnylam Pharmaceuticals stock.